Opus Bio, Miltenyi Biotec deal

Lentigen Corp. changed its name to Opus Bio and sold its lentiviral vector manufacturing business and related assets to Miltenyi, which provides products and services for biomedical research and cellular therapy. The deal includes IP, process technologies and cGMP-qualified manufacturing facilities. Miltenyi granted Opus rights to deploy lentiviral technology in specified therapeutic indications, including chimeric antigen receptor T cell (CAR T)-based therapies and specified therapies for single-gene diseases and disorders. Miltenyi will operate the business from its newly formed U.S. subsidiary, Lentigen Technology Inc., which will be Opus' preferred manufacturing supplier. ...